IN THE SPECIFICATION

A. Please replace the paragraph on page 32, lines 7-25 with the following rewritten paragraph:

(7) an 8- to 10- membered heterobicyclic ring selected from indolyl, benzotriazolyl, benzoimidazolyl, imidazo[4,5-b]pyridinyl, dihydroimidazo[4,5-b]pyridinyl, pyrazolo[4,3-c]pyridinyl, dihydropyrazolo[4,3-c]pyridinyl, tetrahydropyrazolo[4,3-c]pyridinyl, pyrrolo[1,2-a]pyrazinyl, dihydropyrrolo[1,2-a]pyrazinyl, tetrahydropyrrolo[1,2-a]pyrazinyl, octahydropyrrolo[1,2-a]pyrazinyl, isoindolyl, indazolyl, indolinyl, isoindolinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, chromanyl, isochromanyl, hexahydropyrazolo[4,3-c]pyridinyl, hexahydropurinyl, hexahydrooxazolo[3,4-a]pyrazinyl, ~~hexahydrooxazolo[3,4a]pyrazinyl,~~ and 1,2,3,4-tetrahydro-1,8-naphthyridinyl; and wherein the bicyclic ring is unsubstituted or substituted with from 1 to 4 substituents independently selected from:

(a) halogen,
(b) C_{1-6} alkyl,
(c) -O-C_{1-6} alkyl,
(d) C_{1-6} haloalkyl,
(e) -O-C_{1-6} haloalkyl,
(f) -CN,
(g) =O, and
(h) -OH; and

B. Please replace the paragraph bridging pages 86-87 (i.e., page 86, line 31 to page 87, line 15) with the following rewritten paragraph:

(6) an 8- to 10- membered heterobicyclic ring selected from indolyl, benzotriazolyl, benzoimidazolyl, imidazo[4,5-b]pyridinyl, dihydroimidazo[4,5-b]pyridinyl, pyrazolo[4,3-c]pyridinyl, dihydropyrazolo[4,3-c]pyridinyl, tetrahydropyrazolo[4,3-c]pyridinyl, pyrrolo[1,2-a]pyrazinyl, dihydropyrrolo[1,2-a]pyrazinyl, tetrahydropyrrolo[1,2-a]pyrazinyl, octahydropyrrolo[1,2-a]pyrazinyl, isoindolyl, indazolyl, indolinyl, isoindolinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, chromanyl, isochromanyl, hexahydropyrazolo[4,3-c]pyridinyl, hexahydropurinyl, hexahydrooxazolo[3,4-a]pyrazinyl, ~~hexahydrooxazolo[3,4a]pyrazinyl,~~ and 1,2,3,4-tetrahydro-1,8-naphthyridinyl; and wherein the bicyclic ring is unsubstituted or substituted with from 1 to 3 substituents independently selected from:

(a) halogen,
(b) C_{1-4} alkyl,
(c) -O-C_{1-4} alkyl,
(d) C_{1-4} fluoroalkyl,
(e) -O-C_{1-4} fluoroalkyl,
(f) -CN,
(g) =O, and
(h) -OH;

C. Please replace the paragraph on page 117, line 5 with the following rewritten paragraph:

8-hydroxy-5-methyl~~hydroxy-6-methyl~~ -[1,6]naphthyridine-7-carboxylic acid 3,5-dichloro-benzylamide;

D. Please replace the paragraph on page 117, line 7 with the following rewritten paragraph:

8-hydroxy-5-methyl~~hydroxy-6-methyl~~ -[1,6]naphthyridine-7-carboxylic acid 4-fluoro-benzylamide;

E. Please replace the paragraph on page 119, lines 28-29 with the following rewritten paragraph:

1-(7-{[(4-fluorobenzyl)amino]carbonyl}-8-hydroxy-1,6-naphthyridin-5-yl)-L-prolinamide;

F. Please replace the paragraph on page 122, lines 10-11 with the following rewritten paragraph:

N-(2-[(dimethylamino)sulfonyl~~aminosulfonyl~~]-4-fluorobenzyl)-5-(1,1-dioxido-1,2-thiazinan-2-yl)-8-hydroxy-1,6-naphthyridine-7-carboxamide;

G. Please replace the paragraph on page 123, line 28 with the following rewritten paragraph:

8-hydroxy-5-methyl~~hydroxy-6-methyl~~ -[1,6]naphthyridine-7-carboxylic acid 3,5-dichloro-benzylamide;

H. Please replace the paragraph on page 126, lines 28-29 with the following rewritten paragraph:

1-(7-{[(4-fluorobenzyl)amino]carbonyl}-8-hydroxy-1,6-naphthyridin-5-yl)-L-prolinamide;

I. Please replace the paragraph on page 129, lines 13-14 with the following rewritten paragraph:

N-(2-[(dimethylamino)sulfonyl~~aminosulfonyl~~]-4-fluorobenzyl)-5-(1,1-dioxido-1,2-thiazinan-2-yl)-8-hydroxy-1,6-naphthyridine-7-carboxamide;

J. Please replace the paragraph on page 135, lines 29-32 with the following rewritten paragraph:

Representative examples of heterocyclics also include the following bicyclics: hexahydropyrazolo[4,3-c]pyridinyl (e.g., 3a,4,5,6,7,7a-hexahydro-1H-pyrazolo[4,3c]pyridinyl), hexahydropurinyl (e.g., 2,3,4,5,6,7-hexahydro-1H-purinyl), hexahydrooxazolo[3,4-a]pyrazinyl, ~~hexahydrooxazolo[3,4a]pyrazinyl,~~ and 1,2,3,4-tetrahydro-1,8-naphthyridinyl.

K. Please replace the paragraph bridging pages 137-138 (i.e., page 137, line 26 to page 138, line 5) with the following rewritten paragraph:

The present invention also includes a compound of the present invention for use in (a) inhibiting HIV integrase, ~~protease,~~ (b) preventing or treating infection by HIV, or (c) preventing, treating or delaying the onset of AIDS or ARC. The present invention also includes the use of a compound of the present invention as described above as a medicament for (a) inhibiting HIV integrase, (b) preventing or treating infection by HIV, or (c) preventing, treating or delaying the onset of AIDS or ARC. The present invention further includes the use of any of the HIV integrase inhibiting compounds of the present invention as described above in combination with one or more HIV/AIDS treatment agents selected from an HIV/AIDS antiviral agent, an anti-infective agent, and an immunomodulator as a medicament for (a) inhibiting HIV integrase, (b) preventing or treating infection by HIV, or (c) preventing, treating or delaying the onset of AIDS or ARC, said medicament comprising an effective amount of the HIV integrase inhibitor compound and an effective amount of the one or more treatment agents.

L. Please replace the heading of Example 124 on page 256, line 18 with the following rewritten heading:

8-hydroxy-5-methyl~~hydroxy-6-methyl~~ -[1,6]naphthyridine-7-carboxylic acid 3,5-dichloro-benzylamide

M. Please replace the heading of Example 125 on page 259, line 8 with the following rewritten heading:

8-hydroxy-5-methyl~~hydroxy-6-methyl~~ -[1,6]naphthyridine-7-carboxylic acid 4-fluoro-benzylamide ~~(125)~~

N. Please replace the heading of Example 161 on page 293, lines 19-20 with the following rewritten heading:

1-(7-{[(4-fluorobenzyl)amino]carbonyl}-8-hydroxy-1,6-naphthyridin-5-yl)-L-prolinamide